154 related articles for article (PubMed ID: 21038080)
21. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
Bakri SJ; Couch SM; McCannel CA; Edwards AO
Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy.
Mukai R; Kishi S; Sato T; Watanabe G; Matsumoto H
Ophthalmologica; 2010; 224(5):267-73. PubMed ID: 20185940
[TBL] [Abstract][Full Text] [Related]
23. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone.
Yip PP; Woo CF; Tang HH; Ho CK
Br J Ophthalmol; 2009 Jun; 93(6):754-8. PubMed ID: 19273471
[TBL] [Abstract][Full Text] [Related]
24. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
25. Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
Sakai T; Ohkuma Y; Kohno H; Hayashi T; Watanabe A; Tsuneoka H
Br J Ophthalmol; 2014 Dec; 98(12):1642-8. PubMed ID: 25053762
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.
Lee SY; Kim JG; Joe SG; Chung H; Yoon YH
Korean J Ophthalmol; 2008 Jun; 22(2):92-9. PubMed ID: 18612226
[TBL] [Abstract][Full Text] [Related]
27. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization.
Ikuno Y; Nagai Y; Matsuda S; Arisawa A; Sho K; Oshita T; Takahashi K; Uchihori Y; Gomi F
Am J Ophthalmol; 2010 Jan; 149(1):140-6. PubMed ID: 19846061
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
[TBL] [Abstract][Full Text] [Related]
30. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.
Saito M; Iida T; Kano M
Jpn J Ophthalmol; 2013 Mar; 57(2):211-20. PubMed ID: 23208024
[TBL] [Abstract][Full Text] [Related]
31. [Intravitreal bevacizumab injections versus verteporferin photodynamic therapy for macular choroidal neovascularization in high myopia: 24-month follow-up].
El Matri L; Chebil A; Bouraoui R; Kort F; Bouladi M; Basaraih S
J Fr Ophtalmol; 2013 Jan; 36(1):29-34. PubMed ID: 23238073
[TBL] [Abstract][Full Text] [Related]
32. Detailed optical coherence tomography angiographic short-term response of type 3 neovascularization to combined treatment with photodynamic therapy and intravitreal bevacizumab.
Smid LM; Vermeer KA; Wong KT; Martinez Ciriano JP; de Jong JH; Davidoiu V; de Boer JF; van Velthoven MEJ
Acta Ophthalmol; 2021 Mar; 99(2):207-214. PubMed ID: 32602240
[TBL] [Abstract][Full Text] [Related]
33. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
Retina; 2006; 26(9):988-93. PubMed ID: 17151484
[TBL] [Abstract][Full Text] [Related]
34. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
Augustin AJ; Puls S; Offermann I
Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
[TBL] [Abstract][Full Text] [Related]
35. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration.
Navea A; Mataix J; Desco MC; Garcia-Pous M; Palacios E
Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782
[TBL] [Abstract][Full Text] [Related]
36. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
Ngo WK; Chee WK; Tan CS; Lim TH
BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
[TBL] [Abstract][Full Text] [Related]
39. Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration.
Datseris I; Kontadakis GA; Diamanti R; Datseris I; Pallikaris IG; Theodossiadis P; Tsilimbaris MK
Semin Ophthalmol; 2015 Mar; 30(2):112-7. PubMed ID: 24117412
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
